Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Total Non-Current Liabilities (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $117.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 0.73% to $117.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $117.9 million, a 0.73% decrease, with the full-year FY2024 number at $130.0 million, changed N/A from a year prior.
  • Total Non-Current Liabilities was $117.9 million for Q3 2025 at TScan Therapeutics, down from $121.7 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $130.0 million in Q4 2024 to a low of $20.7 million in Q2 2022.
  • A 5-year average of $82.3 million and a median of $99.6 million in 2022 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: crashed 31.99% in 2022, then surged 511.11% in 2023.
  • TScan Therapeutics' Total Non-Current Liabilities stood at $27.2 million in 2021, then skyrocketed by 265.78% to $99.6 million in 2022, then increased by 22.89% to $122.4 million in 2023, then grew by 6.21% to $130.0 million in 2024, then fell by 9.3% to $117.9 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Total Non-Current Liabilities are $117.9 million (Q3 2025), $121.7 million (Q2 2025), and $122.4 million (Q1 2025).